EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations…
27/04/2021 - 6 minutes
Multiple sclerosis
Phase III Fail for MedDay’s Multiple Sclerosis Treatment
A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms…
11/03/2020 - 2 minutes
European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm
Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis…
17/09/2019 - 4 minutes
Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis
An antibody that blocks the action of a hidden viral protein encoded by our genome…
12/03/2019 - 3 minutes
Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’
Altheia Science, based in Milan, has raised €17M to fund the development of gene therapies…
19/12/2018 - 3 minutes
New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech
Spanish biotech Bionure has started an early stage trial of a new drug to treat…
18/05/2018 - 2 minutes
Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II
GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in…
26/03/2018 - 2 minutes
Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial
Just months after the EMA rejected its therapy for Duchenne muscular dystrophy, Swiss company Santhera…
05/03/2018 - 2 minutes
Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies
Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a…
04/01/2018 - 2 minutes
Therapeutic Nanoparticle Companies Are Rare: Meet the CEO of One of Them
In our last BIO Europe interview, I caught up with CEO Timm Jessen of Topas…
15/11/2017 - 4 minutes
German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward
Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates…
02/11/2017 - 2 minutes
Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis
A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in…
01/11/2017 - 2 minutes
